血浆microRNA-510水平与晚期胃癌含奥沙利铂化疗方案疗效的关系

目的 探讨血浆microRNA-510（miR-510）水平与胃癌含奥沙利铂化疗方案疗效的关系。方法 收集本院112例接受含奥沙利铂方案化疗的晚期胃癌患者外周血标本并采用实时定量PCR检测miR-510水平，采用RECIST 1.1版标准评价化疗2个周期后的近期疗效，以CR+PR为敏感组、SD+PD为不敏感组，分析化疗敏感情况与血浆miR-510水平的关系，分析不同血浆miR-510表达患者的远期生存情况。选取同期于本院行健康体检的94例外周血标本为对照。结果 胃癌患者的血浆miR-510水平为3.417±0.574，高于健康体检者的1.017±0.032，差异有统计学意义（P＜0.05）。血浆miR-510表达与胃癌TNM分期、分化程度、淋巴结转移及CEA水平有关（P＜0.05）；112例晚期胃癌患者经2个周期化疗后，获PR 48例、SD 37例、PD 27例，其中化疗敏感48例患者的血浆miR-510为2.362±0.534，低于化疗不敏感者的4.208±0.602，差异有统计学意义（P＜0.05）。全组患者的中位无进展生存期（PFS）和总生存期（OS）分别为7.6个月和11.5个月。以血浆miR-510水平的中位数3.053为界值分为miR-510高水平组和低水平组，其中miR-510高水平组的中位PFS和OS分别为5.3个月和10.2个月，低于miR-510低水平组的8.4个月和12.4个月，差异有统计学意义（P＜0.05）。结论 胃癌患者血浆miR-510水平升高，且与含奥沙利铂方案的化疗敏感性有关，miR-510水平较高者的预后较差，对于预测晚期胃癌患者含奥沙利铂方案的效果及预后有一定价值。

Plasma level of microRNA-510 and efficacy of oxaliplatin-based chemotherapy in advanced gastric cancer

Objective To investigate the relationship between the plasma level of microRNA-510 （miR-510） and efficacy of oxaliplatin-based chemotherapy in advanced gastric cancer. Methods Peripheral blood samples from 112 advanced gastric cancer patients treated with oxaliplatin-based chemotherapy were collected in our hospital. The level of miR-510 was measured by real-time quantitative PCR. The RECIST 1.1 was employed to evaluate the short-term efficacy of oxaliplatin-based chemotherapy in patients after 2 cycles. The patients of CR and PR were assigned as the sensitive group， while those of SD and PD were not sensitive group. The relationship between the sensitivity of chemotherapy and the plasma level of miR-510 were analyzed. The long-term survival of different plasma miR-510 levels were compared according to the follow-up data. In the same period， 94 peripheral blood samples from the hospital’s health examination were selected as control group. Results The relative levels of plasma miR-510 was 3.417±0.574 in patients with gastric cancer， higher than the control group（P＜0.05）. The expression of miR-510 in the plasma of patients with gastric cancer was related to TNM stage， degree of differentiation， lymph node metastasis and CEA level（P＜0.05）. Of the 112 patients with advanced gastric cancer patients after 2 cycles of chemotherapy， there were 48 cases of PR， 37 cases of SD and 27 cases of PD. The plasma level of miR-510 in 48 patients with chemotherapy sensitivity was 2.362±0.534， less than 4.208±0.602 of the patients who were not sensitive to chemotherapy （P＜0.05）. In the whole group， the median progression-free survival （PFS） and overall survival （OS） were 7.6 months and 11.5 months， respectively. The patients were divided into miR-510 high-level group and low-level group according to the median value of 3.053. The median PFS and OS were 5.3 and 10.2 months of miR-510 high-level group， less than 8.4 and 12.4 months of miR-510 low-level group （P＜0.05）. Conclusion The plasma miR-510 levels were elevated in the patients with gastric cancer， and associated with the sensitivity of oxaliplatin in advanced gastric cancer. The patients with higher miR-510 level had a poor prognosis， which has a value for predicting the effect and prognosis of patients with advanced gastric cancer treated with oxaliplatin.